Retrospective analysis of protein kinase C-beta PKC-β expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomasReportar como inadecuado




Retrospective analysis of protein kinase C-beta PKC-β expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Biology Direct

, 2:8

First Online: 21 February 2007Received: 13 February 2007Accepted: 21 February 2007

Abstract

BackgroundBoth mechanistic features and recent correlative findings suggest a potential role for protein kinase C-beta PKC-β in tumor pathogenesis, particularly in B-cell malignancies. To evaluate the role of this gene in lymphoid malignancies, we analyzed global gene expression data to quantify PKC-β expression across diagnostic groups and, when possible, determined correlations between PKC-β expression and survival.

ResultsOur analysis showed that the level of PKC-β expression was highest in chronic lymphocytic leukemia and follicular lymphoma. Within diffuse large-B cell lymphoma DLBCL, PKC-β expression was significantly higher in activated B-cell- like subtype than germinal center B-cell- like subtype P < 0.0001. Elevated PKC-β appeared to be associated with worse survival in both of these subtypes. When analyzed within clinically defined risk groups established by the International Prognostic Index IPI, PKC-β expression was lowest in patients with low IPI scores 0–1. Within intermediate- and high-risk IPI groups, elevated PKC-β expression was associated with worse survival, suggesting that PKC-β may expand the prognostic value of the IPI. Results of global gene expression analyses of DLBCL samples corroborate previous observations that anti-apoptosis, cell proliferation, and B-cell proliferation signaling pathways are functionally related to PKC-β.

ConclusionWe present a first detailed pharmacogenomics report comparing PKC-β mRNA expression across different lymphoid malignancies and evaluating it as an outcome predictor. Our findings suggest that DLBCL patients with elevated PKC-β have a worse prognosis, indicating that further evaluation of PKC-β as a chemotherapeutic target for lymphoid malignancies is warranted.

ReviewersThis article was reviewed by Dr. Pierre Pontarotti, Dr. Kateryna Makova, and Dr. Matthew Coleman nominated by Dr. Sandrine Dudoit.

Electronic supplementary materialThe online version of this article doi:10.1186-1745-6150-2-8 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Shuyu Li - Mark Phong - Michael Lahn - Leslie Brail - Susan Sutton - Boris K Lin - Donald Thornton - Birong Liao

Fuente: https://link.springer.com/article/10.1186/1745-6150-2-8



DESCARGAR PDF




Documentos relacionados